Prelude Therapeutics (PRLD) Corporate presentation summary

Leadership and expertise

• Executive team includes experienced leaders with backgrounds in major biopharma companies and successful drug development track records.

Pipeline and clinical programs

• Advancing a pipeline focused on highly differentiated, clinically validated targets including JAK2V617F, KAT6A, and mutated CALR.

• Lead asset PRT12396, a JAK2V617F mutant selective inhibitor, is in Phase 1 trials for myeloproliferative neoplasms (MF and PV), with IND cleared in January 2026.

• PRT13722, a highly selective oral KAT6A degrader, is on track for IND filing in mid-2026 targeting ER+ breast cancer.

• mCALR-targeted degrader antibody conjugates (DACs) show >100x potency over current clinical CALR antibodies and are positioned for next-generation precision therapies.

Scientific innovation and differentiation

• PRT12396 binds the JAK2 JH2 deep pocket, offering >200x selectivity over JAK1/TYK2 and a 10x therapeutic window, potentially overcoming limitations of first-generation JAK2 inhibitors.

• PRT13722 demonstrates absolute selectivity for KAT6A over KAT6B, robust monotherapy and combination efficacy, and lower bone marrow toxicity compared to dual KAT6A/B inhibitors.

• mCALR DACs leverage SMARCA2/4 degraders for targeted cytotoxicity in CALR-mutant MPNs, with strong in vitro and in vivo activity.